Cigna Group/$CI
1D1W1MYTD1Y5YMAX
Capital at risk
About Cigna Group
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is with the Department of Defense, and it recently won a multiyear deal with top-tier insurer Centene. In health insurance and other benefits, Cigna primarily serves employers through self-funding arrangements, and the company operates mostly in the US with 16 million US and 2 million international medical members covered as of December 2025.
- Ticker
- $CI
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 66,685
- Headquarters
- Bloomfield, United States
- Website
- www.thecignagroup.com
Cigna Group Metrics
BasicAdvanced
$76B
11.95
$24.18
0.32
$6.14
2.16%
Price and volume
Market cap
$76B
Beta
0.32
52-week high
$315.47
52-week low
$239.51
Average daily volume
1.6M
Dividend rate
$6.14
Financial strength
Current ratio
0.846
Quick ratio
0.687
Long term debt to equity
0.678
Total debt to equity
0.743
Dividend payout ratio (TTM)
25.31%
Interest coverage (TTM)
7.78%
Profitability
EBITDA (TTM)
12,758
Gross margin (TTM)
9.14%
Net profit margin (TTM)
2.27%
Operating margin (TTM)
3.90%
Effective tax rate (TTM)
19.17%
Revenue per employee (TTM)
$4,230,000
Management effectiveness
Return on assets (TTM)
4.46%
Return on equity (TTM)
16.76%
Valuation
Price to earnings (TTM)
11.946
Price to revenue (TTM)
0.27
Price to book
1.79
Price to tangible book (TTM)
-2.55
Price to free cash flow (TTM)
8.367
Free cash flow yield (TTM)
11.95%
Free cash flow per share (TTM)
34.529
Dividend yield (TTM)
2.13%
Forward dividend yield
2.16%
Growth
Revenue change (TTM)
7.77%
Earnings per share change (TTM)
32.61%
3-year revenue growth (CAGR)
14.90%
10-year revenue growth (CAGR)
21.97%
3-year earnings per share growth (CAGR)
3.06%
10-year earnings per share growth (CAGR)
12.11%
3-year dividend per share growth (CAGR)
9.32%
10-year dividend per share growth (CAGR)
65.43%
What the Analysts think about Cigna Group
Analyst ratings (Buy, Hold, Sell) for Cigna Group stock.
Analyst projections of the future price of Cigna Group stock.
Bulls say / Bears say
Cigna’s Q2 adjusted EPS of $7.78 surpassed analysts’ expectation of $7.60, prompting management to raise its 2026 adjusted EPS outlook by $0.10 to at least $30.45 (Reuters)
The Evernorth Health Services segment, which includes its PBM and specialty pharmacy units, delivered 6% revenue growth to $61.47 billion in Q2 2026, driven by robust demand for specialty drugs and biosimilars (Reuters)
Cigna’s $100 million investment in its AI-powered Pharmacy Forward program underscores its commitment to enhancing efficiency and margins in its Accredo specialty pharmacy services (Reuters)
Jefferies warns that the potential sale or wind-down of EviCore and its health insurance exchange business could reduce 2027 adjusted operating income by $700 million to $1 billion, with share buybacks unlikely to fully offset the impact (Reuters)
Pressure from GLP-1 weight-loss drug coverage is expected to intensify, with a disclosed $20 million-per-quarter headwind starting in H2 2026 and up to $126 million projected in 2027, challenging PBM profitability (Reuters)
Declining membership among Medicaid, health insurance exchange and Medicare Part D plans, alongside forthcoming state-level PBM reform legislation, could cap margin expansion and create a persistent overhang on Cigna’s PBM business model (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 21 Aug 2026.
Cigna Group Financial Performance
Revenues and expenses
Cigna Group Earnings Performance
Company profitability
Upcoming events
Cigna Group News
AllArticlesVideos
Funds containing Cigna Group
AllEURGBPUSD
Fund name | Fund size | $CI weighting |
|---|---|---|
iShares MSCI World Health Care Sector Advanced€CBUF | €606M | 1.58% |
iShares S&P 500 Health Care Sector€IUHE | €125M | 1.27% |
iShares MSCI USA Quality Dividend ESG£HDIQ | £578M | 0.77% |
iShares MSCI USA SRI$SUAS | $3.4B | 0.54% |
iShares MSCI USA SRI€QDVR | €2.9B | 0.54% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.